See more : GFL Limited (GFLLIMITED.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Sientra, Inc. (SIEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sientra, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Ember Therapeutics, Inc. (EMBT) Income Statement Analysis – Financial Results
- Deutsche Bank Aktiengesellschaft (DBK.DE) Income Statement Analysis – Financial Results
- Fresh Vine Wine, Inc. (VINE) Income Statement Analysis – Financial Results
- GME Group Holdings Limited (8188.HK) Income Statement Analysis – Financial Results
- United Tennessee Bankshares, Inc. (UNTN) Income Statement Analysis – Financial Results
Sientra, Inc. (SIEN)
About Sientra, Inc.
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.55M | 80.68M | 71.24M | 83.70M | 68.13M | 36.54M | 20.73M | 38.11M | 44.73M | 35.17M | 10.45M |
| Cost of Revenue | 48.96M | 36.35M | 32.30M | 33.01M | 26.82M | 14.17M | 6.88M | 10.65M | 11.50M | 8.59M | 2.35M |
| Gross Profit | 41.59M | 44.34M | 38.94M | 50.69M | 41.30M | 22.37M | 13.85M | 27.45M | 33.23M | 26.58M | 8.10M |
| Gross Profit Ratio | 45.94% | 54.95% | 54.66% | 60.56% | 60.63% | 61.22% | 66.82% | 72.04% | 74.29% | 75.57% | 77.49% |
| Research & Development | 14.06M | 10.46M | 10.31M | 13.54M | 10.95M | 9.81M | 9.70M | 7.20M | 4.71M | 4.48M | 3.67M |
| General & Administrative | 41.53M | 31.77M | 38.19M | 46.77M | 42.42M | 41.54M | 23.58M | 18.74M | 10.71M | 18.08M | 9.94M |
| Selling & Marketing | 55.05M | 48.46M | 52.55M | 80.19M | 67.72M | 33.91M | 20.61M | 25.76M | 23.60M | 22.23M | 17.92M |
| SG&A | 96.58M | 80.23M | 90.74M | 126.96M | 110.13M | 75.45M | 44.18M | 44.50M | 34.31M | 40.31M | 27.86M |
| Other Expenses | 12.00K | 6.56M | 111.00K | -55.00K | 39.00K | -95.00K | -36.00K | 360.00K | 2.15M | -46.00K | -1.00K |
| Operating Expenses | 110.64M | 90.69M | 101.06M | 140.50M | 121.08M | 85.26M | 53.89M | 51.70M | 39.02M | 44.79M | 31.53M |
| Cost & Expenses | 159.60M | 127.03M | 133.36M | 173.51M | 147.90M | 99.43M | 60.77M | 62.35M | 50.52M | 53.38M | 33.88M |
| Interest Income | 130.00K | 4.00K | 206.00K | 1.41M | 532.00K | 172.00K | 63.00K | 32.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.53M | 8.25M | 9.45M | 4.57M | 3.43M | 1.23M | 98.00K | 3.10M | 2.17M | 872.00K | 0.00 |
| Depreciation & Amortization | 6.78M | 10.93M | 4.41M | 9.05M | 3.32M | 3.03M | 1.18M | 318.00K | 275.00K | 280.00K | 288.00K |
| EBITDA | -62.27M | -46.35M | -70.31M | -103.57M | -75.88M | -59.78M | -38.48M | -38.53M | -3.64M | -17.97M | -23.15M |
| EBITDA Ratio | -68.77% | -43.91% | -81.00% | -96.49% | -111.38% | -163.59% | -192.95% | -62.60% | -8.13% | -51.10% | -221.55% |
| Operating Income | -69.05M | -46.35M | -62.12M | -89.81M | -79.77M | -62.89M | -40.03M | -38.53M | -5.79M | -18.21M | -23.43M |
| Operating Income Ratio | -76.26% | -57.45% | -87.19% | -107.30% | -117.10% | -172.10% | -193.08% | -101.10% | -12.93% | -51.77% | -224.29% |
| Total Other Income/Expenses | -4.23M | -16.15M | -4.96M | -16.97M | -2.86M | -1.16M | -71.00K | -2.71M | -26.00K | -918.00K | -1.00K |
| Income Before Tax | -73.69M | -62.50M | -89.91M | -106.78M | -82.63M | -64.05M | -40.11M | -41.23M | -5.81M | -19.13M | -23.43M |
| Income Before Tax Ratio | -81.38% | -77.46% | -126.21% | -127.58% | -121.29% | -175.26% | -193.43% | -108.20% | -12.99% | -54.38% | -224.30% |
| Income Tax Expense | 27.00K | 21.00K | 33.00K | 34.00K | -4.00K | -17.00K | 61.00K | 3.14M | 4.04M | 826.00K | -1.00K |
| Net Income | -73.72M | -62.52M | -89.95M | -106.82M | -82.63M | -64.03M | -40.17M | -41.23M | -5.81M | -19.13M | -23.43M |
| Net Income Ratio | -81.41% | -77.49% | -126.26% | -127.62% | -121.29% | -175.22% | -193.72% | -108.20% | -12.99% | -54.38% | -224.30% |
| EPS | -10.27 | -10.96 | -17.91 | -26.27 | -32.53 | -33.42 | -22.03 | -26.14 | -22.83 | -20.90 | -25.61 |
| EPS Diluted | -10.27 | -10.96 | -17.91 | -26.27 | -32.53 | -33.42 | -22.03 | -26.14 | -22.83 | -20.90 | -25.61 |
| Weighted Avg Shares Out | 7.17M | 5.71M | 5.02M | 4.07M | 2.54M | 1.92M | 1.82M | 1.58M | 254.54K | 915.12K | 915.12K |
| Weighted Avg Shares Out (Dil) | 7.18M | 5.71M | 5.02M | 4.07M | 2.54M | 1.92M | 1.82M | 1.58M | 254.54K | 915.12K | 915.12K |
Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction
Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra's breast reconstruction and augmentation business
Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
Company secures $22.5 million of new money in debtor-in-possession financing from existing lenders to support ongoing operations during the sale process Company secures $22.5 million of new money in debtor-in-possession financing from existing lenders to support ongoing operations during the...
Sientra, Inc. (SIEN) Q3 2023 Earnings Call Transcript
Sientra, Inc. (NASDAQ:SIEN ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Oliver Bennett - Chief Legal, Compliance and Corporate Development Officer Ron Menezes - President and Chief Executive Officer Denise Dajles - Chief Technical...
Sientra Reports Third Quarter Financial and Operational Results
IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third...
Sientra to Present at the Stifel 2023 Healthcare Conference
IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its participation at the Stifel 2023 Healthcare...
Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook
IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal...
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
The best short-squeeze stocks to buy now can be a perilous territory in the investment landscape. However, they also possess the potential for astronomical returns.
Sientra (SIEN) Reports Q2 Loss, Lags Revenue Estimates
Sientra (SIEN) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $2.90 per share a year ago.
Sientra Reports Record Second Quarter Financial and Operational Results
Revenue growth of 7.5% driven by continued market share gains in reconstruction and augmentation Best operational results in company history with 95% and 63% year-over-year improvement in operating cash flow and adjusted EBITDA respectively Continued success in advancing products through...
Sientra to Report Second Quarter 2023 Financial Results on August 10, 2023
IRVINE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN)(“Sientra” or the “Company”), a medical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced that it will release financial results for...
Source: https://incomestatements.info
Category: Stock Reports